- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Nirav Jhaveri wird neuer CFO bei Longeveron | 1 | Investing.com Deutsch | ||
| Mi | Longeveron Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| Mi | Longeveron appoints new chief financial officer | 1 | Seeking Alpha | ||
| Mi | Longeveron Appoints Nirav Jhaveri as Chief Financial Officer | 79 | GlobeNewswire (Europe) | Mr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector MIAMI, Aug. 19, 2026... ► Artikel lesen | |
| 13.08. | Longeveron expects ELPIS II HLHS data in mid-september while cash runway extends into Q4 2026 | 1 | Seeking Alpha | ||
| 12.08. | Longeveron GAAP EPS of -$0.19 in-line, revenue of $0.28M misses by $0.05M | 1 | Seeking Alpha | ||
| 12.08. | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| LONGEVERON Aktie jetzt für 0€ handeln | |||||
| 12.08. | Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update | 215 | GlobeNewswire (Europe) | On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric... ► Artikel lesen | |
| 11.08. | Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition | 1 | GlobeNewswire (USA) | ||
| 29.07. | Longeveron Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 23.07. | Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors | 1 | GlobeNewswire (USA) | ||
| 14.07. | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 10.07. | Longeveron Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 07.07. | Longeveron CFO Lisa Locklear To Step Down; Marie Washburn Appointed As Successor | 1 | RTTNews | ||
| 06.07. | Longeveron Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.07. | Longeveron names Marie Washburn as CFO | 1 | Seeking Alpha | ||
| 06.07. | Longeveron Appoints Marie Washburn as Chief Financial Officer | 150 | GlobeNewswire (Europe) | Ms. Washburn has over 20 years of experience in leadership roles in the pharmaceutical and biotech sectorsCorporate focus on delivering top-line results from the Phase 2b clinical trial evaluating... ► Artikel lesen | |
| 09.06. | Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA) | 1 | GlobeNewswire (USA) | ||
| 05.06. | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 04.06. | Longeveron to Present at BIO International Convention 2026 | 17 | GlobeNewswire (USA) |
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BB BIOTECH | 58,90 | -0,51 % | Edison Investment Research Limited: Edison issues report on BB Biotech (BION) | Edison Investment Research Limited
Edison issues report on BB Biotech (BION) 28-Jul-2026 / 14:20 GMT/BST
The issuer is solely responsible for the content of this announcement.
... ► Artikel lesen | |
| VALNEVA | 2,945 | +1,24 % | Valneva: EMA startet Prüfung des Lyme-Borreliose-Impfstoffs | Pfizer und Valneva haben mit ihrem gemeinsam entwickelten Lyme-Borreliose-Impfstoffkandidaten PF-07307405 einen wichtigen regulatorischen Schritt in Europa erreicht. Die Europäische Arzneimittel-Agentur... ► Artikel lesen | |
| EPIGENOMICS | 0,910 | -24,17 % | PTA-Adhoc: Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2026 | DJ PTA-Adhoc: Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2026
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR Schlagwort(e): Geschäftszahlen / Halbjahr
Epigenomics... ► Artikel lesen | |
| BIOFRONTERA | 2,350 | -2,89 % | Biofrontera outlines September 28, 2026 PDUFA date and expects sBCC launch in Q1 2027 amid ITC lamp remediation | ||
| HEIDELBERG PHARMA | 2,510 | 0,00 % | Heidelberg Pharma: Was die Halbjahreszahlen über die Zukunft verraten | Bei Biotech-Unternehmen sagt eine einzelne Zahlenreihe selten alles, doch manchmal markiert sie einen Wendepunkt. Bei der Heidelberg Pharma AG (ISIN: DE000A11QVV0) könnte der Mitte Juli vorgelegte Halbjahresbericht... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 49,970 | -2,61 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results | ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026. "The second quarter reflected... ► Artikel lesen | |
| BIOXXMED | 1,000 | 0,00 % | PTA-News: bioXXmed AG: Einladung zur Hauptversammlung | DJ PTA-News: bioXXmed AG: Einladung zur Hauptversammlung
Unternehmensmitteilung für den Kapitalmarkt
bioXXmed AG: Einladung zur Hauptversammlung
Heidelberg (pta000/20.07.2026/15:45... ► Artikel lesen | |
| OCUGEN | 1,196 | -5,38 % | Ocugen Provides Business Update with Second Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,106 | -0,36 % | INOVIO shares jump 18% after Q2 beat | ||
| CLINUVEL | 6,474 | +7,58 % | Clinuvel Pharmaceuticals Ltd - 6-K, Report of foreign issuer | ||
| INFLARX | 1,780 | -2,20 % | InflaRx NV: Durchbruch in der Immuntherapie weckt weltweites Interesse | ||
| INTELLIA THERAPEUTICS | 10,700 | -5,98 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates | Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of MedicineAnticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S.... ► Artikel lesen | |
| BAVARIAN NORDIC | 25,580 | -0,85 % | Bavarian Nordic A/S: Bavarian Nordic Receives European Commission Approval of Mpox/Smallpox Vaccine for Children Aged 2 to Less than 12 Years | MVA-BN approval expanded to include children aged 2 to less than 12 years for protection against mpox, smallpox and disease caused by vaccinia virusApproval further strengthens MVA-BN's position in... ► Artikel lesen | |
| EDITAS MEDICINE | 2,600 | -6,47 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 58,02 | -2,32 % | BioMarin Pharmaceutical Inc.: BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline | BioMarin to pay $275 million upfront, plus additional payments upon achievement of development and regulatory milestones
Alesta to spin out all non-ALE1 assets... ► Artikel lesen |
LONGEVERON INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,008 (+0,94 %) liegt der Kurs bei 0,830 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LONGEVERON INC finden Sie auf Wallstreet Online.